Sepsis in Chimeric Antigen Receptor T-Cell Therapy: A Six-Year Nationwide Analysis of Clinical Outcomes and Healthcare Resource Utilization in Hospitalizations for Hematologic Malignancies.
Infections during CAR T-cell therapy are rare but serious, occurring in 6% of hospitalizations with high mortality.
The study quantified the clinical burden of sepsis during CAR T-cell therapy hospitalizations. Sepsis occurred in 6.2% of hospitalizations and was associated with 28.7% in-hospital mortality versus 1.1% without sepsis.
What the study was
- Study design
- Retrospective nationwide hospitalization database study
- Population
- 10450 weighted CAR T-cell therapy hospitalizations for hematologic malignancies
- Sample size
- 10450
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Transplantation and cellular therapy
Why it surfaced
The large nationwide analysis identifies a major safety burden in CAR T care, though administrative data cannot establish causality
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.